Skip to main content
Premium Trial:

Request an Annual Quote

Roche and Ionian Technologies Strike Product-Development Pact

NEW YORK (GenomeWeb News) – Roche Diagnostics will collaborate with molecular diagnostics company Ionian Technologies in an effort to identify new applications and customers for Ionian's technology.

Ionian said on Thursday that Roche will seek new opportunities for Ionian's NEAR Assay, a rapid isothermal nucleic acid amplification technology, in return for exclusive manufacturing rights if the new applications are commercialized.

Ionian's technology is aimed at applications in human in vitro diagnostics, food safety, biodefense, agriculture, and veterinary applications.

The San Diego-based company said that its technology enables DNA and RNA detection from bacterial or viral pathogens in less than ten minutes.

The collaboration will allow the company "to focus on its core strengths, including technology and assay development, while leveraging the business development, sales, and manufacturing expertise of Roche," Ionian's CEO Andrew Miller said in a statement.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.